Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1

Research output: Contribution to journalArticle

166 Citations (Scopus)

Abstract

Specific tyrosine kinase inhibitors (TKIs) are rapidly developing clinical tools applied for the inhibition of malignant cell growth and metastasis formation. Most of these newly developed TKI molecules are hydrophobic, thus rapidly penetrate the cell membranes to reach intracellular targets. However, a large number of tumor cells overexpress multidrug transporter membrane proteins, which efficiently extrude hydrophobic drugs and thus may prevent the therapeutic action of TKIs. In the present work, we demonstrate that the most abundant and effective cancer multidrug transporters, MDR1 and MRP1, directly interact with several TKIs under drug development or already in clinical trials. This interaction with the transporters does not directly correlate with the hydrophobicity or molecular structure of TKIs, and shows a large variability in transporter selectivity and affinity. We suggest that performing enzyme- and cell-based multidrug transporter interaction tests for TKIs may greatly facilitate drug development, and allow the prediction of clinical TKI resistance based on this mechanism. Moreover, diagnostics for the expression of specific multidrug transporters in the malignant cells, combined with information on the interactions of the drug transporter proteins with TKIs, should allow a highly effective, individualized clinical treatment for cancer patients.

Original languageEnglish
Pages (from-to)318-325
Number of pages8
JournalBiochimica et Biophysica Acta - Molecular Basis of Disease
Volume1587
Issue number2-3
DOIs
Publication statusPublished - Jul 18 2002

Fingerprint

P-Glycoprotein
Protein-Tyrosine Kinases
Pharmaceutical Preparations
Neoplasms
Molecular Structure
Hydrophobic and Hydrophilic Interactions
Drug Interactions
Membrane Proteins
Cell Count
Cell Membrane
Clinical Trials
Neoplasm Metastasis
Enzymes
Therapeutics
Growth

Keywords

  • Chemotherapy
  • MDR1
  • MRP
  • Multidrug resistance
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Biophysics

Cite this

@article{3befa1cf29f14b678d7b4977c2139e05,
title = "Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1",
abstract = "Specific tyrosine kinase inhibitors (TKIs) are rapidly developing clinical tools applied for the inhibition of malignant cell growth and metastasis formation. Most of these newly developed TKI molecules are hydrophobic, thus rapidly penetrate the cell membranes to reach intracellular targets. However, a large number of tumor cells overexpress multidrug transporter membrane proteins, which efficiently extrude hydrophobic drugs and thus may prevent the therapeutic action of TKIs. In the present work, we demonstrate that the most abundant and effective cancer multidrug transporters, MDR1 and MRP1, directly interact with several TKIs under drug development or already in clinical trials. This interaction with the transporters does not directly correlate with the hydrophobicity or molecular structure of TKIs, and shows a large variability in transporter selectivity and affinity. We suggest that performing enzyme- and cell-based multidrug transporter interaction tests for TKIs may greatly facilitate drug development, and allow the prediction of clinical TKI resistance based on this mechanism. Moreover, diagnostics for the expression of specific multidrug transporters in the malignant cells, combined with information on the interactions of the drug transporter proteins with TKIs, should allow a highly effective, individualized clinical treatment for cancer patients.",
keywords = "Chemotherapy, MDR1, MRP, Multidrug resistance, Tyrosine kinase inhibitor",
author = "T. Hegedűs and L. Őrfi and Attila Seprodi and A. V{\'a}radi and B. Sarkadi and G. K{\'e}ri",
year = "2002",
month = "7",
day = "18",
doi = "10.1016/S0925-4439(02)00095-9",
language = "English",
volume = "1587",
pages = "318--325",
journal = "Biochimica et Biophysica Acta - Molecular Basis of Disease",
issn = "0925-4439",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1

AU - Hegedűs, T.

AU - Őrfi, L.

AU - Seprodi, Attila

AU - Váradi, A.

AU - Sarkadi, B.

AU - Kéri, G.

PY - 2002/7/18

Y1 - 2002/7/18

N2 - Specific tyrosine kinase inhibitors (TKIs) are rapidly developing clinical tools applied for the inhibition of malignant cell growth and metastasis formation. Most of these newly developed TKI molecules are hydrophobic, thus rapidly penetrate the cell membranes to reach intracellular targets. However, a large number of tumor cells overexpress multidrug transporter membrane proteins, which efficiently extrude hydrophobic drugs and thus may prevent the therapeutic action of TKIs. In the present work, we demonstrate that the most abundant and effective cancer multidrug transporters, MDR1 and MRP1, directly interact with several TKIs under drug development or already in clinical trials. This interaction with the transporters does not directly correlate with the hydrophobicity or molecular structure of TKIs, and shows a large variability in transporter selectivity and affinity. We suggest that performing enzyme- and cell-based multidrug transporter interaction tests for TKIs may greatly facilitate drug development, and allow the prediction of clinical TKI resistance based on this mechanism. Moreover, diagnostics for the expression of specific multidrug transporters in the malignant cells, combined with information on the interactions of the drug transporter proteins with TKIs, should allow a highly effective, individualized clinical treatment for cancer patients.

AB - Specific tyrosine kinase inhibitors (TKIs) are rapidly developing clinical tools applied for the inhibition of malignant cell growth and metastasis formation. Most of these newly developed TKI molecules are hydrophobic, thus rapidly penetrate the cell membranes to reach intracellular targets. However, a large number of tumor cells overexpress multidrug transporter membrane proteins, which efficiently extrude hydrophobic drugs and thus may prevent the therapeutic action of TKIs. In the present work, we demonstrate that the most abundant and effective cancer multidrug transporters, MDR1 and MRP1, directly interact with several TKIs under drug development or already in clinical trials. This interaction with the transporters does not directly correlate with the hydrophobicity or molecular structure of TKIs, and shows a large variability in transporter selectivity and affinity. We suggest that performing enzyme- and cell-based multidrug transporter interaction tests for TKIs may greatly facilitate drug development, and allow the prediction of clinical TKI resistance based on this mechanism. Moreover, diagnostics for the expression of specific multidrug transporters in the malignant cells, combined with information on the interactions of the drug transporter proteins with TKIs, should allow a highly effective, individualized clinical treatment for cancer patients.

KW - Chemotherapy

KW - MDR1

KW - MRP

KW - Multidrug resistance

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0037130294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037130294&partnerID=8YFLogxK

U2 - 10.1016/S0925-4439(02)00095-9

DO - 10.1016/S0925-4439(02)00095-9

M3 - Article

C2 - 12084474

AN - SCOPUS:0037130294

VL - 1587

SP - 318

EP - 325

JO - Biochimica et Biophysica Acta - Molecular Basis of Disease

JF - Biochimica et Biophysica Acta - Molecular Basis of Disease

SN - 0925-4439

IS - 2-3

ER -